KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short term Debt (2020 - 2025)

Historic Short term Debt for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Q3 2025 value amounting to $11.2 million.

  • Supernus Pharmaceuticals' Short term Debt fell 7588.07% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 7588.07%. This contributed to the annual value of $47.3 million for FY2024, which is 908.39% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Short term Debt stood at $11.2 million for Q3 2025, which was down 7588.07% from $30.0 million recorded in Q1 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Short term Debt registered a high of $401.4 million during Q3 2022, and its lowest value of $11.2 million during Q3 2025.
  • For the 5-year period, Supernus Pharmaceuticals' Short term Debt averaged around $79.1 million, with its median value being $46.2 million (2023).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Short term Debt skyrocketed by 160317.35% in 2022, and later tumbled by 9483.17% in 2023.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Short term Debt stood at $44.8 million in 2021, then tumbled by 52.9% to $21.1 million in 2022, then soared by 146.54% to $52.1 million in 2023, then dropped by 9.08% to $47.3 million in 2024, then tumbled by 76.27% to $11.2 million in 2025.
  • Its Short term Debt stands at $11.2 million for Q3 2025, versus $30.0 million for Q1 2025 and $47.3 million for Q4 2024.